Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 30 | 30 | 0 |
| Shares | 16.1M | 15.3M | −824.9K (−5.1%) |
| Value | $49.2M | $48.9M | −$322.0K (−0.7%) |
New holders (5)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 26,100 | $78.8K | 0.00% |
| EverSource Wealth Advisors, LLC | 5,000 | $15.1K | 0.00% |
| Raymond James Financial Inc | 1,189 | $3.59K | 0.00% |
| FMR LLC | 5 | $15 | 0.00% |
| Global Retirement Partners, LLC | 1 | $3 | 0.00% |
Sold out (5)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Wealthedge Investment Advisors, LLC | 73,971 | $226.4K |
| SG Americas Securities, LLC | 16,585 | $51.0K |
| HRT Financial LP | 10,149 | $31.0K |
| Bryn Mawr Trust Co | 250 | $765 |
| Larson Financial Group LLC | 125 | $383 |